In this study, we focus on the ΔITILELP mutation, the only mutation reported that sometimes leads to severe forms, inconsistent with its residual transported activity. ΔITILELP is a deletion that eliminates a consensus site on N66, one of the protein's seven glycosylation sites. Our hypothesis was that the ΔITILELP mutant is less stable and undergoes faster degradation.
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SUMMARY
Cystinosis is a rare autosomal recessive lysosomal storage disorder characterized by intralysosomal accumulation of cystine. The causative gene for cystinosis is CTNS, which encodes the protein cystinosin, a lysosomal proton-driven cystine transporter. Over 100 mutations have been reported, leading to varying disease severity, often in correlation with residual cystinosin activity as a transporter and with maintenance of its protein-protein interactions.
In this study, we focus on the ΔITILELP mutation, the only mutation reported that sometimes leads to severe forms, inconsistent with its residual transported activity. ΔITILELP is a deletion that eliminates a consensus site on N66, one of the protein's seven glycosylation sites. Our hypothesis was that the ΔITILELP mutant is less stable and undergoes faster degradation.
Our dynamic SILAC study clearly showed that wild-type cystinosin is very stable, while ΔITILELP is degraded three times more rapidly. Additional lysosome inhibition experiments confirmed ΔITILELP instability and showed that the degradation was mainly lysosomal. We observed that in the lysosome, ΔITILELP is still capable of interacting with the V-ATPase complex and some members of the mTOR pathway, similar to the wild-type protein. Intriguingly, our interactomic and immunofluorescence studies showed that ΔITILELP is partially retained at the endoplasmic reticulum (ER). We proposed that the ΔITILELP mutation causes protein misfolding, ER retention and inability to be processed in the Golgi apparatus, and we demonstrated that ΔITILELP carries high-mannose glycans on all six of its remaining glycosylation sites. We found that the high turnover of ITILELP, due to its immature glycosylation state in combination with low transport activity, might be responsible for the phenotype observed in some patients.
Data are available via ProteomeXchange with identifier PXD004948, PXD005357 and on Panorama Public at https://panoramaweb.org/labkey/Guerrera.url.
INTRODUCTION
Cystinosis (OMIM 219800) is a rare autosomal recessive lysosomal storage disorder characterized by intralysosomal accumulation of cystine, leading to impaired function of multiple organs (1) . Based on the age of onset and severity of symptoms, three clinical forms of cystinosis have been described: infantile (severe), juvenile and ocular (mild).
The causative gene for cystinosis is CTNS, which encodes the protein cystinosin, a lysosomal protondriven cystine transporter (2, 3, 4) . Recently, we have shown that in addition to transporting cystine, cystinosin is involved in nutrient-sensing in kidney proximal tubular cells via interactions with v-ATPase, Ragulator and Rags (5) , and that the lack of cystinosin results in dysregulation of the mTOR signaling pathway.
Cystinosin is a 367-amino-acid (AA) protein with a nominal mass of 41.7 kDa. It has a short cytosolic 10-AA C-terminal tail, seven transmembrane (TM) domains spanning the lysosomal membrane and a 128-AA N-terminal region in the lysosomal lumen bearing seven N-glycosylation consensus sites N-X-S/T (N36, N41, N51, N66, N84, N104 and N107, hereafter referred to as N1 to N7) ( Figure 1A ). The molecular weight (MW) of mature cystinosin is estimated at approximately 56 kDa. Cystinosin contains two lysosomal targeting motifs: a classical tyrosine-based motif (GYDQL) in the C-terminal tail and a conformational signal located on the fifth inter-TM loop (3, 6) .
Most early functional studies conducted on a set of 31 cystinotic mutations revealed a correlation between cystine transport activity and severity of symptoms (4) . Most infantile mutations abolished cystine transport, whereas less severe mutations only reduced it (4) . Patients affected by severe symptoms harbor severe mutations on both alleles, while patients with milder forms usually carry nonsevere mutations on both alleles or in association with a severe mutation.
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However, some discrepancies have been observed, such as with I67-P73del (ΔITILELP), which leads to 19% residual transport activity and is considered a non-severe mutation (4) . Individuals with the ΔITILELP mutation on both alleles have the juvenile form, whereas those with the ΔITILELP mutation on one allele in association with the 57 kb deletion (the most common severe mutation) can develop the infantile form (7) (8) (9) . ΔITILELP is an in-frame deletion adjacent to an N-glycosylation site at position 66. The ΔITILELP mutation (deletion of AA67-73) is predicted to prevent the recognition consensus sequence of N-glycosylation N-X-S/T on NIT (AA66-68) by oligosaccaryltransferase. Therefore, ΔITILELP results in the removal of seven amino acids in the N-terminal luminal region and the loss of glycosylation on N66, the fourth of seven N-glycosylation sites (10) . To date, ΔITILELP is the only mutation detected in patients that leads to faulty glycosylation.
As glycosylation of lysosomal membrane proteins is known to protect from proteolysis (11), we hypothesized that faulty glycosylation caused by ΔITILELP might influence the stability of the protein. To investigate the stability of ΔITILELP, we compared its degradation rate to wild-type (WT) cystinosin. As additional controls, we also studied the degradation of two mutations that do not impact glycosylation sites (N288K and N323K). The classical approach for protein-turnover studies is pulse-chase labeling with radioactive amino acids. We used an alternative approach based on mass spectrometry, known as dynamic stable isotope-labeling by amino acids in cell culture (dynamic SILAC) (12, 13) . In this metaboliclabeling time-course experiment, the ratio of the unlabeled and labeled peptides of a protein reflects the ratio of pre-existing and newly synthesized proteins at each measured time point. It has been shown that from these values, the degradation rate of the proteins can be successfully calculated by curve-plotting or mathematical formulas (14, 12) .
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To expand our knowledge of the cellular mechanisms involved in the pathogenicity of ΔITILELP, we analyzed its fate in the cell by studying its glycosylation, cellular localization and specific protein partners, as compared to WT cystinosin.
EXPERIMENTAL PROCEDURES Antibodies
Antibodies were obtained from the following sources: antibody to PDI and calnexin from Enzo Life Sciences, antibody to GFP from Roche, anti-mouse IgG-HRP from GE Healthcare, and Alexa Fluor 555- 
Cell culture
NIH/3T3 fibroblast cell lines were grown in DMEM supplemented with 10% foetal bovine serum (FBS), 100 U/mL penicillin, 0.1 mg/mL streptomycin and 2 mM L-glutamine (complete DMEM medium) (all from Life Technologies).
For dynamic SILAC studies, NIH/3T3 cells stably expressing different fusion proteins were plated at 4×10 ThermoFisher), 100 mg/L proline (Sigma-Aldrich), 100 U/mL penicillin, 0.1 mg/mL streptomycin and 2 mM L-glutamine for chase periods of 0, 6, 18 and 24 h. At these times, the cells were treated for immunoprecipitation before being processed for proteomic turnover analysis.
To calculate the cell-growth rate (D), WT and mutant cells were plated in 10-cm tissue-culture dishes at 1.3×10 6 cells per 150-mm cell-culture dish, cultivated for 24 h, collected at several time-points (0, 6, 18 and 24 h) and then counted using the Beckman Coulter Z2 cell counter. The cell growth rate (D) was calculated by fitting the number of cells (y) at different times (x) to an exponential growth curve in Microsoft Excel, using the formula: y = a * eDx, where "a" is the number of cells at 0 h.
Generation of stable cell lines
To generate NIH/3T3 fibroblast cell lines stably expressing human protein cystinosin-EGFP, the construct pCTNS-EGFP (3) was sub-cloned into the lentiviral pRRL.SIN.cPPT.PGK/WPRE vector (15) . The cystinosin mutants ΔITILELP, N288K, N323K (5) and N1N7 (the seven putative N-glycosylated sites mutated in alanine) were obtained by the modification of the pRRL.SIN.cPPT.PGK/WPRE-CTNS-EGFP construct with specific mutagenic primers using the Stratagene QuikChange® Site-Directed Mutagenesis Kit according to the manufacturer's recommendations. Lentiviruses were produced in HEK293T cells as previously described (5) . NIH/3T3 cells were transduced by lentiviral particles containing CTNS-EGFP or its mutated forms at an MOI of 7 in the presence of 8 µg/mL polybrene.
Generation of EGFP fusion constructs and transfection of NIH/3T3 fibroblasts
The pCTNS-EGFP construct and its mutant form ΔITILELP have been described previously (3) . For the mutant N66A (the N66 glycosylation site mutated in alanine), the modification of the pCTNS-EGFP construct (3) was carried out using the Stratagene QuikChange Site-Directed Mutagenesis Kit according to the manufacturer's recommendations. NIH/3T3 fibroblasts were transfected with 2 µg of the different constructs using Lipofectamine® 2000 reagent (Invitrogen) according to the manufacturer's protocol.
Cells were lysed 48 h after transfection for western blotting. Three independent biological replicates were analyzed, and for each experiment, colocalization GFP:PDI or GFP:Lamp1 for five cells of each cell type was performed.
Co-immunoprecipitation and immunoblotting
PNGase F and Endo H treatments
Cell lysates were treated for 1 h at 37°C with 100 U of PNGase F or Endo H (BioLabs) per µg of total proteins according to the manufacturer's recommendations except for the denaturation step, which was done at 50°C instead of 100°C. The resulting cell lysates were analysed by western blotting.
Drug treatment and FACS analysis
NIH/3T3 cells stably expressing WT cystinosin-EGFP and ΔITILELP-EGFP were incubated with 10 µM clasto-lactacystin β-lactone (Calbiochem) or 100 nM bafilomycin A1 (SIGMA) for 24 h in the complete 9 DMEM medium. Cells were then harvested by using trypsin, and centrifuged for 2.5 min at 1500 rpm.
The cell pellets were washed once with PBS and resuspended in 500 µl PBS with 1% bovine serum albumin. EGFP expression was analyzed by direct flow cytometry using 
Mass spectrometry (MS) analysis for turnover study
For turnover studies, immunoprecipitated protein samples were resolved by SDS-PAGE on 10% gel and large protein bands corresponding to cystinosin were excised. In-gel trypsin digestion was performed as previously described (5). Nano-LC-MS/MS analysis of in-gel digested samples was performed on an Ultimate 3000 Rapid Separation Liquid Chromatography (RSLC) system coupled to a Q-Exactive Plus mass spectrometer (Thermo Scientific, Waltham, MA, USA). Extracted peptides were resuspended in 0.1% (v/v) trifluoroacetic acid and 10% acetonitrile, then loaded onto a µ-precolumn (Acclaim PepMap 100 C18, cartridge, 300 µm i.d.×5 mm, 5 µm, Dionex), followed by separation on the analytical 50-cm nano column (0.075 mm ID, Acclaim PepMap 100, C18, 2 µm, Dionex). The chromatography solvents were (A) 0.1% formic acid in water, and (B) 80% acetonitrile with 0.08% formic acid. Peptides were eluted from the column using a gradient from 5% to 40% B over 38 min, then analyzed by data-dependent MS/MS, using the top-10 acquisition method. Briefly, the instrument settings were as follows: resolution was set to 70,000 for MS scans and 17,500 for the data-dependent MS/MS scans to increase speed. The MS AGC target was set to 3. 
Turnover data analysis
The loss of a protein can be calculated from the relative isotope abundance (RIA) at each time point. The
RIA represents the portion of the residual pre-existing protein (MS1 area of the light peptides: A L ) versus the total amount of the protein in the cell, both pre-existing (A L ) and newly synthesized (MS1 area of the heavy peptides: A H ), at each time-point. RIA is therefore calculated as: The rate of degradation (K deg ) was calculated as the difference between the rate of loss (K loss ) and the cell-growth rate (D):
At least three independent biological replicates were analyzed (four for WT cystinosin-EGFP, three for ΔITILELP, N288K, N323K and N1N7). For each experiment, three to four peptides were measured at 0, 6, 18 and 24 h (details in Table S1 ). Each mutant was always run in parallel with WT cystinosin-EGFP. The cell-growth rate (D) was measured in at least two independent experiments for each sample (four for WT cystinosin-EGFP, two each for ΔITILELP, N323K, N288K and N1N7) (details in Table S3 ). Statistical analysis using one-way ANOVA was performed with Prism version 7 (GraphPad software), using K loss values obtained by curve-fitting and formulas, from at least three independent experiments and three to four peptides per time-point. The threshold for statistical significance was set at p˂0.05. Each bar represents the mean ± SD.
Mass spectrometry analysis for interactomic study
For interactomic analysis, co-immunoprecipitated protein samples were concentrated on top of 10% SDS-PAGE gel and excised. In-gel trypsin digestion was performed as previously described (5) . Analysis by LC-MS/MS was performed as described in "Mass spectrometry (MS) analysis for turnover study", except for gradient length, which was 120 min rather than 38 min. The mass spectrometry proteomics data and details on the identifications and quantifications have been deposited at the ProteomeXchange Consortium via the PRIDE (17) partner repository with the dataset identifier PXD004948.
Interactomic data analysis of the MS files was processed with MaxQuant software version 1.5. mass and fragment ions, we set initial mass deviations of 4.5 ppm and 20 ppm, respectively. The minimum peptide length was set at seven amino acids and strict specificity for trypsin cleavage was required, allowing up to two missed cleavage sites. Carbamidomethylation (Cys) was set as a fixed modification, whereas oxidation (Met) and N-terminal acetylation were set as variable modifications.
Match-between-runs was allowed using default parameters. The false discovery rate (FDR) for PSM and protein identification was set to 1%, determined by a target-decoy approach. Scores were calculated in MaxQuant as previously described, and left as the default parameters (18) . The reverse-and commoncontaminant hits were removed from the MaxQuant output. Proteins were quantified according to the MaxQuant label-free algorithm using Label-free Quantification LFQ intensities (19 For MS turnover studies, we performed a minimum of three independent biological replicates (four for WT cystinosin-EGFP, three each for ΔITILELP, N288K, N323K and N1N7). For each experiment, three to four peptides were measured at 0, 6, 18 and 24 h (details in Table S1 ). Each mutant was always run in parallel with WT cystinosin-EGFP. The cell-growth rate (D) was measured in at least two independent experiments for each sample (four for WT cystinosin-EGFP, two each for ΔITILELP, N323K, N288K and N1N7) (details in Table S3 ). Statistical analysis using one-way ANOVA was performed with Prism version 7 (GraphPad software) using K loss values obtained by a formula (threshold p˂0.05) (details in Table S4a ). 
RESULTS
Detection of EGFP-tagged cystinosin peptides by MS
To analyze the turnover of WT and mutated cystinosin, we transduced 3T3 cells with lentiviral constructs to stably express the cystinosin-EGFP fusion protein and its mutated forms. The schematic representation of WT cystinosin and ΔITILELP can be found in Figure 1A and 1B. We consistently identified specific cystinosin peptides in accordance with the WT or the mutated forms N288K and N323K ( Figure S1 ). In all analyzed forms of cystinosin, we could identify the peptide AA23-33 (SVSLTVPPVVK). These data suggest that the signal peptide of cystinosin was cleaved after S22, generating a new N-terminal sequence starting with SVSLTVPPVVK, despite previous reports describing an uncleavable signal peptide (3, 21) . Our data agreed with the prediction of the currently used algorithm (http://www.cbs.dtu.dk/services/SignalP) ( Figure S2 ).
ΔITILELP-EGFP mutation results in the loss of seven amino acids and one N-glycosylation site (N66);
consequently, its expected molecular mass would be approximately 3 kDa smaller than that of WT cystinosin, if all remaining sites were fully glycosylated. However, the observed molecular mass of the glycosylated form was much lower than expected and inconsistent with the simple deletion of seven amino acids and the loss of one glycan ( Figure 1C) . Again, the detection of the peptide SVSLTVPPVVK ( Figure 1B ) for ΔITILELP indicated that the N-terminal domain of the mutated protein was intact.
To further verify the effect of the glycan in position 66 (N66) on the protein electrophoretic profile, we substituted the N-glycosylated site N66 with alanine (N66A). N66A showed a molecular mass shift compared to WT cystinosin that was consistent with the loss of one glycan ( Figure 1C ).
Half-life of cystinosin and ΔITILELP
To investigate whether N-glycosylation influences the stability of ΔITILELP, we measured protein degradation using a dynamic SILAC approach. We incubated unlabelled cells expressing cystinosin and ΔITILELP with [ At each time-point, cystinosin and its mutants were immunoprecipitated and analyzed by LC-MS/MS. For each sample, the MS analysis was performed to confirm the presence of cystinosin or its mutants and to verify the incorporation of labelled amino acids during the time-course. For calculating the turnover rate of a given protein, we used the precursor ion signal (MS1 area) from four labelled and unlabelled peptides from that protein at each time-point (an example for one peptide is shown in Figure 2 ). The extracted MS1 areas were used to calculate the relative isotope abundance at each time point (RIA t ) for each cell type and each replicate (Table S1) . RIA L at time 0 was always set to 1 because the cells Figure S3 ). The cells expressing cystinosin and its mutants were counted at each time-point to determine the cell-growth rate or dilution rate (D) ( Table   S3 ).
The reproducibility of the measurements reported on the exponential decay curves between three different independent biological replicates appeared to be very high ( Figure 3 ) (16). The WT cystinosin was found to be very stable, with K loss =0.0434±0.008, while ΔITILELP was degraded three times faster than WT cystinosin, with K loss =0.1291±0.014 ( Figure 3 , Table S2 ). The division rates of cells overexpressing cystinosin-EGFP and ΔITILELP-EGFP were similar, indicating that the loss rate of ΔITILELP was due to increased degradation (Figure 3 histograms, Table S4 ). N288K and N323K showed a tendency, though not significant, toward increased degradation when compared to WT cystinosin. Strikingly, the substitution of seven asparagine residues with alanine residues (N1N7), mimicking complete deglycosylation, resulted in a very stable protein with a turnover similar to that of WT cystinosin ( Figure   3 ).
Cystinosin and ΔITILELP lysosomal degradation
To confirm the higher degradation rate of ΔITILELP, fibroblasts expressing ΔITILELP-EGFP or cystinosin-EGFP were treated for 24 h with bafilomycin A1 (Baf A1), an activity-inhibitor of lysosomes and other acidic compartments. EGFP fluorescence was then measured by flow cytometry. Upon Baf A1 treatment, the EGFP signal was significantly increased for both WT cystinosin and ΔITILELP when compared to DMSO-treated cells (vehicle), indicating that both proteins undergo lysosomal degradation. To test whether the proteasome partially contributes to the degradation of ΔITILELP, the same fibroblasts were treated with clasto-lactacystin β-lactone (CL), a specific proteasome inhibitor. In the fibroblasts expressing cystinosin-EGFP or ΔITILELP-EGFP, the EGFP fluorescence intensity did not change after 24 h of CL treatment, suggesting that proteasome degradation does not contribute significantly to the increased loss of ΔITILELP (Figure 4 ).
ER retention of ΔITILELP
To investigate whether the ΔITILELP mutation impacts protein-protein interactions, we explored the interactome of ΔITILELP compared to that of WT cystinosin by MS. We compared proteins coimmunoprecipitated by WT cystinosin or by ΔITILELP, then identified 181 such proteins as potentially specific interactants of WT cystinosin and/or ΔITILELP, as they were not identified in the negative control (without GFP) ( Table S5 ). The results of this MS analysis largely confirmed our previously published interaction network generated for WT cystinosin (5), as we identified eight subunits of the vacuolar type H + -ATPase (V-ATPase) and Rag GTPase C ( Figure 5 , full protein list in Table S5 ). ΔITILELP maintained the same protein-protein interactions as WT cystinosin in the lysosome. However, ΔITILELP, but not WT cystinosin, specifically co-immunoprecipitated 17 proteins directly implicated in protein-processing in the ER ( Figure 5 ).
We investigated the cellular distribution of WT cystinosin and its mutants in cells stably overexpressing EGFP-tagged proteins by immunofluorescence. WT cystinosin-EGFP presented a predominant colocalization with the late endosomal-lysosomal marker Lamp-1 (83.62±1.73%) and a minor colocalization with protein disulfide isomerase (PDI), an ER marker (15.64±2.28%). Similar to WT cystinosin, N288K and N323K showed predominant lysosomal localization in 3T3 cells. In striking contrast, the signal for ΔITILELP corresponding to an ER localization was higher (48.26±2.57%), along with a decreased punctuated late endosomal-lysosomal localization pattern (47.66±2.01%) ( Figure 6A and 6B).
Multitransmembrane proteins that do not acquire proper configurations accumulate in the ER, where they are recognized by calnexin (22) . To analyze the interaction between cystinosin and this chaperone, lysates of 3T3 cells stably expressing cystinosin-EGFP or its mutated forms were immunoprecipitated with anti-GFP antibody, and co-immunoprecipitated endogenous calnexin was detected by western blotting. As expected from the localization data, interactions with calnexin were significantly increased for ΔITILELP compared to WT cystinosin, N288K or N323K ( Figure 6C and 6D) . The mutants N66A and N1N7 appeared to localize at the lysosome as well, without any ER retention ( Figure S4 ). Together, these data indicate that the ΔITILELP mutation leads to partial retention of cystinosin in the ER due to misfolding of the protein.
N-linked high-mannose glycans of ΔITILELP
Lysosomal transmembrane proteins are synthesized in the ER, where folding and the initial stages of glycosylation (high-mannose type glycans) occur. They are then targeted to lysosomes via the trans-Golgi network, acquiring further modifications (complex type N-glycans). To verify the glycosylation stage of WT cystinosin and ΔITILELP, we performed enzymatic deglycosylation using the peptide:N-glycosidase F enzyme (PNGase F), which removes all N-linked glycan residues. As a control, we used N1N7, the constitutively deglycosylated form of cystinosin. After incubation with PNGase F, WT cystinosin had the migration profile of N1N7, while N1N7 did not show any changes ( Figure 7A) , showing that WT cystinosin is indeed heavily glycosylated. ΔITILELP was also completely deglycosylated by PNGase F, showing that it also contains a certain level of glycosylation. N288K and N323K, used as positive controls, showed the same electrophoretic profile as WT cystinosin.
We therefore tested the effect of the Endoglycosidase H enzyme (Endo H), as it specifically hydrolyses non-mature N-glycans (high-mannose type). In contrast to WT cystinosin, ΔITILELP was sensitive to Endo H digestion ( Figure 7B ), suggesting that ΔITILELP carries high-mannose on its available glycosylation sites.
WT cystinosin is not affected by Endo H digestion, confirming that the WT form contains complex-type glycans, acquired during maturation in the Golgi apparatus.
DISCUSSION
In this study, we investigated the impact of cystinosin deletion ITILELP on the stability of the protein.
The ITILELP mutation disrupts the proper glycosylation of cystinosin on N66. In the homozygous state, ITILELP leads to juvenile cystinosis, which correlates with the ability to maintain minimal cystine transport activity in vitro (9) . However, when found in the heterozygous state together with a 57 kb deletion on the second allele, the ITILELP mutation can result in the development of the severe infantile phenotype (7, 8) . These surprising observations led us to hypothesize that the deletion of seven amino acids, together with the lack of glycosylation on N66, interferes with cystinosin stability.
To investigate ITILELP turnover, we used the dynamic SILAC approach with MS. However, we faced two main challenges. First, cystinosin is not easily detectable by MS in non-fractionated samples, such as a total cell lysate or blood (no records on peptide identification in proteomic studies are reported at nextprot.org). This is probably due to the very low abundance of endogenous cystinosin in cells and to characteristics of its sequence, which contains seven TM domains and seven glycosylation sites. To our knowledge, endogenous cystinosin was identified with two peptides in only one MS study of enriched lysosomal membranes (23) . Furthermore, no good antibodies are available to immunoprecipitate endogenous cystinosin from cell lysates in order to enrich endogenous cystinosin. For these reasons, we developed cellular models of stably expressing EGFP-tagged WT and mutated cystinosin. Although these tagged proteins localize correctly in the lysosome and have been previously used for functional studies,
we are aware that the use of EGFP-tagged cystinosin is a constraint and we cannot be certain that the endogenous proteins follow exactly the same behaviour. In this study, we detected four peptides of cystinosin (two from WT cystinosin and two specific to mutants) and provided evidence that the Nterminal signal peptide can be cleaved before S23.
The second challenge was that dynamic SILAC, although a well-established approach, can be tricky when studying the turnover of stable proteins. We calculated the K loss from the MS1 areas of the peptides and 20 their labelled counterparts using curve-fitting or mathematical formulas applied to each time-point (reported in different forms in the literature, but equivalent) (14, 16) . Our data confirmed that the K loss values calculated by curve-fitting and mathematical formulas correlate perfectly when many data points are used in the calculations. However, stable proteins such as WT cystinosin are virtually undegraded during the cell cycle/lifespan (rate of degradation: K deg ), and are only diluted upon cell division. In this case, the rate of loss (K loss ) of the protein is very close to the cell-division rate (D), and the K deg =K loss −D value nearly reaches zero. After verifying that D was similar for all of the cell lines studied, we chose to report and compare the K loss of WT cystinosin and the mutants.
Our dynamic SILAC data showed that WT cystinosin is a very stable protein and that the ITILELP mutation increased three-fold the degradation of the protein, while the N288K and N323K mutations did not significantly influence the protein's stability. We clearly showed that ITILELP undergoes lysosomal processing (e.g. calreticulin, Os9, Sel1l) (24) . Immunofluorescence studies confirmed these findings and showed the partial localization of ITILELP in the ER and in lysosomes.
The accumulation of misfolded proteins in the ER can lead to ER stress and cell death. To prevent cell injury, non-native proteins can exit the ER to undergo proteasomal and/or lysosomal degradation (25, 26) . To better understand the reasons for ER retention, we further explored the extent of the faulty glycosylation of ITILELP and demonstrated that it carried immature high-mannose glycans in all six remaining sites not directly affected by the mutation, suggesting that it is prevented from reaching the Golgi network for further processing. This is coherent with the observed ITILELP molecular weight by SDS-PAGE. Several studies have been conducted to decipher the glyco-code of processed proteins, revealing the importance of N-glycans in directing protein maturation (27) . The glycan composition controls the calnexin binding cycle, which is important for the recognition of misfolded proteins in the ER (28, 29) . Along these lines, the strong interaction shown in our study between ITILELP and the ER chaperone, calnexin, suggested that this mutant was recognized as a non-native protein by the ER quality-control system and was partially retained in this compartment. The N1N7 mutant, which does not carry any glycosylation, is correctly directed from the ER to the lysosome and its stability is not affected.
We suggest that ITILELP is initially retained in the ER, preventing it from being processed in the Golgi to obtain mature glycosylation, but it is directly transported to lysosome via its two targeting sequences.
Further studies will be necessary to fully understand the escape mechanisms of ITILELP from the ER to the lysosome. One possible mechanism is ER macro-autophagy that may be induced by ER stress (30) .
However, some unconventional cellular mechanisms of ER escape by retained proteins have also been described. Non-mature CFTR can be targeted to the plasma membrane, skipping the Golgi compartment via the unconventional GRASP-dependent pathway (31) . Additionally, the formation of ER-derived 22 vesicles referred to as EDEMosomes, which are necessary for ERAD tuning, enable the removal of selected ERAD regulators from the ER and their degradation by proteasomes and endolysosomal proteases. These vesicles contain EDEM1 and Sel1L but can also carry other ER proteins (32) .
We conclude that the high turnover of ITILELP, due to its immature glycosylation state together with low transport activity, might be responsible for the phenotype observed in some patients who carry this mutation heterozygously, together with the 57 kb deletion. 
